Abstract Background and aims CADASIL, the most common monogenic cause of ischemic stroke and small vessel disease, can also cause episodic encephalopathy with migraine and focal deficits. However, no disease-specific therapy exists. Compared to controls, CADASIL patients have decreased ratios of l-arginine to asymmetric dimethylarginine. They also demonstrate more robust improvement of cerebral vasoreactivity from l-arginine. We aimed to examine l-arginine as a direct treatment. Methods This case report describes l-arginine treatment in a CADASIL patient with prolonged migrainous encephalopathy and receptive aphasia. Results A 47-year-old woman presented with receptive aphasia, confusion, right homonymous hemianopia, mild right-sided weakness, and severe headache. Symptoms developed across two days after a noxious smell exposure. MRI showed left parietal vascular congestion and subtle gyriform diffusion restriction, as well as T2 hyperintensities typical for CADASIL. CT angiogram, continuous EEG monitoring and CSF examination were unrevealing. Family history was consistent with CADASIL. Headache resolved with ketorolac and metoclopramide, but her profound aphasia remained unchanged over 7 days. A test dose of oral l-arginine was well-tolerated. The dose was increased to a supraphysiologic 3 grams three times daily, and aphasia Rachael Schutz: nothing to disclose. Figure 1 - belongs to Results
Building similarity graph...
Analyzing shared references across papers
Loading...
Marlan Kay
Rachael Schutz
European Stroke Journal
EvergreenHealth
Building similarity graph...
Analyzing shared references across papers
Loading...
Kay et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69fd7e00bfa21ec5bbf063bc — DOI: https://doi.org/10.1093/esj/aakag023.422